EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC.
How has EGFR-NSCLC impacted people’s lives?
- Total incident population of NSCLC in 7MM was 484,726 in 2017
- The incident cases of EGFR mutation in the United States in 2017 was 37,370
- The incident population of EGFR-NSCLC in the United States contributed around 34% of the total population of EGFR mutated NSCLC in the 7MM in 2017
- Among the EU5 countries, Germany had the highest incident population of NSCLC, and that was 29%
How will Disease transform EGFR-NSCLC Market?
- Market Drivers
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity and Approval
- Increasing Incidence of NSCLC
- Rich Pipeline and label expansion of approved therapies
- Cost-Effectiveness of Therapies
- Small Patient Populations for Specific Subsets of NSCLC
- Generic or Biosimilar Erosion
- Market Barriers
- Cost-Effectiveness of Therapies
- Small Patient Populations for Specific Subsets of NSCLC
- Generic or Biosimilar Erosion
“EGFR- NSCLC market size in 7MMwas USD 1,893 million in 2017”
“EGFR- NSCLC market size in 7MMwas USD 1,893 million in 2017”
Which biotechnical companies are developing EGFR-NSCLC drugs?
The dynamics of the EGFR-NSCLC market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in the development of drugs for EGFR-NSCLC.
Key players, such as Takeda, Yuhan Corporation/ Janssen Research & Development, Novartis, Janssen Research & Development, and others are involved in developing drugs for EGFR-NSCLC treatment market.
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/